antirheumatic effect of JAK-inhibitors

Kunihiro Yamaoka, Satoshi Kubo, Koshiro Sonomoto, Yoshiya Tanaka, Keisuke Maeshima

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Treatment of rheumatoid arthritis (RA) has dramatically developed with the use of biologics targeting inflammatory cytokines. However, expense and parenteral use can cause issues in the initiation and continuation of the treatment. Therefore a new orally available antirheumatic drug has been long-awaited. Recently, small-molecule compounds targeting Janus kinase (JAK) has shown clinical efficacy similar to biologics in clinical trials for active RA. Among the JAK-inhibitors, new drug application for tofacitinib is concurrently under review in western and asian countries and is highly expected to become a new antirheumatic drug in the near future. In order to evaluate the mode of action, we utilized peripheral blood and synovium from RA patients. Proliferation and cytokine production of CD4+ T cell was prominently reduced and subsequently inhibited cartilage destruction by the synovium. Our result is in line with the inhibitory effect of tofacitinib on joint destruction in RA patients those who were treated with tofacitinib. Therefore, further clinical efficacy is expected in the in the long-term treatment with tofacitinib.

Original languageEnglish
Pages (from-to)112-117
Number of pages6
JournalJapanese Journal of Clinical Immunology
Volume35
Issue number2
DOIs
Publication statusPublished - 2012
Externally publishedYes

Fingerprint

Janus Kinases
Rheumatoid Arthritis
Antirheumatic Agents
Synovial Membrane
Biological Products
Cytokines
Cartilage
Therapeutics
Joints
Clinical Trials
T-Lymphocytes
tofacitinib
Pharmaceutical Preparations

Keywords

  • Janus kinase
  • rheumatoid arthritis
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Yamaoka, K., Kubo, S., Sonomoto, K., Tanaka, Y., & Maeshima, K. (2012). antirheumatic effect of JAK-inhibitors. Japanese Journal of Clinical Immunology, 35(2), 112-117. https://doi.org/10.2177/jsci.35.112

antirheumatic effect of JAK-inhibitors. / Yamaoka, Kunihiro; Kubo, Satoshi; Sonomoto, Koshiro; Tanaka, Yoshiya; Maeshima, Keisuke.

In: Japanese Journal of Clinical Immunology, Vol. 35, No. 2, 2012, p. 112-117.

Research output: Contribution to journalArticle

Yamaoka, K, Kubo, S, Sonomoto, K, Tanaka, Y & Maeshima, K 2012, 'antirheumatic effect of JAK-inhibitors', Japanese Journal of Clinical Immunology, vol. 35, no. 2, pp. 112-117. https://doi.org/10.2177/jsci.35.112
Yamaoka K, Kubo S, Sonomoto K, Tanaka Y, Maeshima K. antirheumatic effect of JAK-inhibitors. Japanese Journal of Clinical Immunology. 2012;35(2):112-117. https://doi.org/10.2177/jsci.35.112
Yamaoka, Kunihiro ; Kubo, Satoshi ; Sonomoto, Koshiro ; Tanaka, Yoshiya ; Maeshima, Keisuke. / antirheumatic effect of JAK-inhibitors. In: Japanese Journal of Clinical Immunology. 2012 ; Vol. 35, No. 2. pp. 112-117.
@article{a7900a91e20a461f9a8f55b56c5bc79a,
title = "antirheumatic effect of JAK-inhibitors",
abstract = "Treatment of rheumatoid arthritis (RA) has dramatically developed with the use of biologics targeting inflammatory cytokines. However, expense and parenteral use can cause issues in the initiation and continuation of the treatment. Therefore a new orally available antirheumatic drug has been long-awaited. Recently, small-molecule compounds targeting Janus kinase (JAK) has shown clinical efficacy similar to biologics in clinical trials for active RA. Among the JAK-inhibitors, new drug application for tofacitinib is concurrently under review in western and asian countries and is highly expected to become a new antirheumatic drug in the near future. In order to evaluate the mode of action, we utilized peripheral blood and synovium from RA patients. Proliferation and cytokine production of CD4+ T cell was prominently reduced and subsequently inhibited cartilage destruction by the synovium. Our result is in line with the inhibitory effect of tofacitinib on joint destruction in RA patients those who were treated with tofacitinib. Therefore, further clinical efficacy is expected in the in the long-term treatment with tofacitinib.",
keywords = "Janus kinase, rheumatoid arthritis, tyrosine kinase inhibitors",
author = "Kunihiro Yamaoka and Satoshi Kubo and Koshiro Sonomoto and Yoshiya Tanaka and Keisuke Maeshima",
year = "2012",
doi = "10.2177/jsci.35.112",
language = "English",
volume = "35",
pages = "112--117",
journal = "Immunological Medicine",
issn = "0911-4300",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - antirheumatic effect of JAK-inhibitors

AU - Yamaoka, Kunihiro

AU - Kubo, Satoshi

AU - Sonomoto, Koshiro

AU - Tanaka, Yoshiya

AU - Maeshima, Keisuke

PY - 2012

Y1 - 2012

N2 - Treatment of rheumatoid arthritis (RA) has dramatically developed with the use of biologics targeting inflammatory cytokines. However, expense and parenteral use can cause issues in the initiation and continuation of the treatment. Therefore a new orally available antirheumatic drug has been long-awaited. Recently, small-molecule compounds targeting Janus kinase (JAK) has shown clinical efficacy similar to biologics in clinical trials for active RA. Among the JAK-inhibitors, new drug application for tofacitinib is concurrently under review in western and asian countries and is highly expected to become a new antirheumatic drug in the near future. In order to evaluate the mode of action, we utilized peripheral blood and synovium from RA patients. Proliferation and cytokine production of CD4+ T cell was prominently reduced and subsequently inhibited cartilage destruction by the synovium. Our result is in line with the inhibitory effect of tofacitinib on joint destruction in RA patients those who were treated with tofacitinib. Therefore, further clinical efficacy is expected in the in the long-term treatment with tofacitinib.

AB - Treatment of rheumatoid arthritis (RA) has dramatically developed with the use of biologics targeting inflammatory cytokines. However, expense and parenteral use can cause issues in the initiation and continuation of the treatment. Therefore a new orally available antirheumatic drug has been long-awaited. Recently, small-molecule compounds targeting Janus kinase (JAK) has shown clinical efficacy similar to biologics in clinical trials for active RA. Among the JAK-inhibitors, new drug application for tofacitinib is concurrently under review in western and asian countries and is highly expected to become a new antirheumatic drug in the near future. In order to evaluate the mode of action, we utilized peripheral blood and synovium from RA patients. Proliferation and cytokine production of CD4+ T cell was prominently reduced and subsequently inhibited cartilage destruction by the synovium. Our result is in line with the inhibitory effect of tofacitinib on joint destruction in RA patients those who were treated with tofacitinib. Therefore, further clinical efficacy is expected in the in the long-term treatment with tofacitinib.

KW - Janus kinase

KW - rheumatoid arthritis

KW - tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84922685811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922685811&partnerID=8YFLogxK

U2 - 10.2177/jsci.35.112

DO - 10.2177/jsci.35.112

M3 - Article

AN - SCOPUS:84922685811

VL - 35

SP - 112

EP - 117

JO - Immunological Medicine

JF - Immunological Medicine

SN - 0911-4300

IS - 2

ER -